Advertising in the medicinal cannabis sector in Australia is unlike any other area of healthcare marketing. Clinics and brands face a unique challenge: navigating the overlapping requirements of both the Therapeutic Goods Administration (TGA) and AHPRA/National Boards. With prescription-only status and some of the strictest advertising restrictions in the world, even seemingly small details—like wording on a website, use of imagery, or patient testimonials—can be deemed unlawful promotion.

This article unpacks the key rules from both regulators, clarifies what clinics and brands can and cannot say, and highlights safer strategies to build awareness without risking compliance.

Registered nurses with appropriate training and experience will be able to prescribe Schedule 2, 3, 4, and 8 medicines under a collaborative prescribing model. In this blog post, we explore how this systemic change brings both opportunity and responsibility.

In the latest addition to our Market Insights series that explores the Australian medicinal cannabis space, we look into patient demographics and how patients access plant-based medicines.

We sat down with industry trailblazer, Irena Katz of We Are Lux, to discuss her journey within the medicinal cannabis industry as a qualified naturopath and passionate cannabis advocate. In this post, we explore how Irena's personal experience, purpose, and bold vision has made her a strong patient advocate and industry innovator — and how these qualities have also helped shape her store We Are Lux.

For businesses looking to enter or maximise their presence within the medicinal cannabis market, understanding the evolving prescriber landscape and access pathways is crucial to navigate this dynamic market effectively.